BCYRN1, a c-MYC-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer

Cancer Cell International

Yu-Run Lu¹  Tao Hu¹ 

[1]Sichuan Provincial People’s Hospital, No. 32, Section 2, 1st Ring Road (West), Chengdu City 610072, China

关键词: NSCLC (non-small-cell lung cancer);    Metastasis;    c-MYC;    lncRNA (long non-coding RNA);    BCYRN1 (brain cytoplasmic RNA 1);   

Others  :  1171057
DOI  :  10.1186/s12935-015-0183-3

 received in 2014-12-01, accepted in 2015-03-16,  发布年份 2015

【 摘 要 】

Background

Long non-coding RNAs (lncRNAs) are increasingly implicated in the regulation of the progression of malignancy.

Aim

To clarify the relations among BCYRN1 (brain cytoplasmic RNA 1, a long non-coding RNA), c-MYC and cell metastasis of non-small-cell lung cancer (NSCLC).

Methods

Real-time PCR was used to measure expression of BCYRN1 in NSCLC. Knockdown and overexpression of c-MYC were respectively performed using shRNA and lentivirus to investigate its effect on BCYRN1 expression. BCYRN1 was respectively knockdown and overexpressed by siRNA and BCYRN1 mimics to investigate its role in regulating cell metastasis in vitro. ChIP (chromatin immunoprecipitation) assay was performed to confirm the binding of c-MYC to the promoter of BCYRN1. Expression levels of matrix metalloproteinases (MMP9 and MMP13) were determined using real-time PCR and Western blotting.

Results

BCYRN1 is upregulated and targeted by c-MYC in NSCLC, leading to the increase of cell motility and invasiveness. RNA interference and lentivirus infection showed a positive correlation between the expressions of c-MYC and BCYRN1. ChIP assay confirmed the binding of c-MYC to the promoter region of BCYRN1 gene. In-vitro cell metastasis experiments demonstrated that BCYRN1 was necessary in the c-MYC-regulated cell migration and invasion. The mRNA and protein expression levels of MMP9 and MMP13 descended with the decreasing BCYRN1 level and ascended with the upregulation of BCYRN1.

Conclusion

These findings uncover a regulatory mechanism in NSCLC cells involving the metastasis-promoting lncRNA BCYRN1 that improves expressions of the key metastasis-supporting proteins MMP9 and MMP13.

【 授权许可】

   
2015 Hu and Lu; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Stewart BW, Wild C: World cancer report 2014: World Health Organization. 2014.
• [2]Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
• [3]Kawabata S, Chiang C-T, Memmott RM, Komiya T, Gills JJ, Dennis PA: Rapamycin decreases expression of thymidylate synthase and enhances the response to pemetrexed in preclinical studies and a Phase I/II clinical study of subjects with non-small cell lung cancer. Cancer Res 2014, 74(19 Supplement):2927.
• [4]Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, et al.: MYC is a metastasis gene for non-small-cell lung cancer. PLoS One 2009, 4(6):e6029.
• [5]Bu D, Yu K, Sun S, Xie C, Skogerbø G, Miao R, et al. NONCODE v3.0: integrative annotation of long noncoding RNAs. Nucleic Acids Research 2012 Jan;40(Database issue):D210-5. doi: 10.1093/nar/gkr1175.
• [6]Tsai M-C, Spitale RC, Chang HY: Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 2011, 71(1):3-7.
• [7]Xu C, Yang M, Tian J, Wang X, Li Z: MALAT-1: a long non-coding RNA and its important 3′end functional motif in colorectal cancer metastasis. Int J Oncol 2011, 39(1):169-75.
• [8]Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al.: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464(7291):1071-6.
• [9]Schmidt LH, Spieker T, Koschmieder S, Humberg J, Jungen D, Bulk E, et al.: The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011, 6(12):1984-92.
• [10]Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, et al.: MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett 2010, 584(22):4575-80.
• [11]Chen W, Böcker W, Brosius J, Tiedge H: Expression of neural BC200 RNA in human tumours. J Pathol 1997, 183(3):345-51.
• [12]Redvers RP, Anderson RL: Long Non-Coding RNA: Agent Provocateur in Breast Cancer Metastasis. 2000.
• [13]Iacoangeli A, Lin Y, Morley EJ, Muslimov IA, Bianchi R, Reilly J, et al.: BC200 RNA in invasive and preinvasive breast cancer. Carcinogenesis 2004, 25(11):2125-33.
• [14]Han J-Y, Kim HS, Lee SH, Park WS, Lee JY, Yoo NJ: Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003, 41(1):65-70.
• [15]Hofmann H-S, Hansen G, Richter G, Taege C, Simm A, Silber R-E, et al.: Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non–small cell lung cancer patients. Clin Cancer Res 2005, 11(3):1086-92.
• [16]Zhuang D, Mannava S, Grachtchouk V, Tang W, Patil S, Wawrzyniak J, et al.: C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 2008, 27(52):6623-34.
• [17]Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A, et al.: Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012, 119(2):411-21.
• [18]Schomber T, Kalberer CP, Wodnar-Filipowicz A, Skoda RC: Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells. Blood 2004, 103(12):4511-3.
• [19]Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X, et al.: Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 2010, 10(1):318. BioMed Central Full Text
• [20]Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, et al.: Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 2005, 33(1):44-50.
• [21]Singla AK, Thirukkumaran C, Dixit R, Wu W. Genomic Landscape of Cancer Metastasis. In: Next Generation Sequencing in Cancer Research. Springer; 2013: 75–90.
• [22]Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. In: Semin Cancer Biol: 2006: Elsevier; 2006: 253–264.
• [23]He T-C, Sparks AB, Rago C, Hermeking H, Zawel L, Da Costa LT, et al.: Identification of c-MYC as a target of the APC pathway. Science 1998, 281(5382):1509-12.
• [24]Wang J, Kobayashi T, Floc’h N, Kinkade CW, Aytes A, Dankort D, et al.: B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 2012, 72(18):4765-76.
• [25]Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L: CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res 2011, 9(2):161-72.
• [26]Nabeshima K, Inoue T, Shimao Y, Sameshima T: Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002, 52(4):255-64.
• [27]Friedl P, Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003, 3(5):362-74.
• [28]Bourguignon LY, Gunja-Smith Z, Iida N, Zhu H, Young L, Muller WJ, et al.: CD44v3,8–10 Is Involved in Cytoskeleton-Mediated Tumor Cell Migration and Matrix Metalloproteinase (MMP-9) Association in Metastatic Breast Cancer Cells. J Cell Physiol 1998, 176(1):206-15.
• [29]Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P: Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004, 49(3):179-86.
• [30]Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. In: Seminars in cancer biology: 2000: Elsevier; 2000: 415–433.
• [31]Ghosh S, Basu M, Roy SS: ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J Biol Chem 2012, 287(18):15001-15.